Axsome Therapeutics, Inc. (0HKF.L)
USD 104.95
(0.17%)
USD 104.95
(0.17%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 270.6 Million USD | 440.8% |
| 2022 | 50.03 Million USD | 0.0% |
| 2021 | - USD | 0.0% |
| 2020 | - USD | 0.0% |
| 2019 | - USD | 0.0% |
| 2018 | - USD | 0.0% |
| 2017 | - USD | 0.0% |
| 2016 | - USD | 0.0% |
| 2015 | - USD | 0.0% |
| 2014 | - USD | 0.0% |
| 2013 | - USD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 74.99 Million USD | 4.85% |
| 2024 Q2 | 87.16 Million USD | 16.22% |
| 2023 Q2 | 46.7 Million USD | -50.62% |
| 2023 Q4 | 71.53 Million USD | 23.77% |
| 2023 Q3 | 57.79 Million USD | 23.76% |
| 2023 Q1 | 94.57 Million USD | 288.06% |
| 2023 FY | 270.6 Million USD | 440.8% |
| 2022 Q4 | 24.37 Million USD | 44.67% |
| 2022 Q2 | 8.81 Million USD | 0.0% |
| 2022 Q1 | - USD | 0.0% |
| 2022 FY | 50.03 Million USD | 0.0% |
| 2022 Q3 | 16.84 Million USD | 91.0% |
| 2021 Q3 | - USD | 0.0% |
| 2021 Q4 | - USD | 0.0% |
| 2021 Q1 | - USD | 0.0% |
| 2021 Q2 | - USD | 0.0% |
| 2021 FY | - USD | 0.0% |
| 2020 FY | - USD | 0.0% |
| 2020 Q3 | - USD | 0.0% |
| 2020 Q2 | - USD | 0.0% |
| 2020 Q1 | - USD | 0.0% |
| 2020 Q4 | - USD | 0.0% |
| 2019 Q1 | - USD | 0.0% |
| 2019 Q4 | - USD | 0.0% |
| 2019 Q3 | - USD | 0.0% |
| 2019 FY | - USD | 0.0% |
| 2019 Q2 | - USD | 0.0% |
| 2018 FY | - USD | 0.0% |
| 2018 Q4 | - USD | 0.0% |
| 2018 Q3 | - USD | 0.0% |
| 2018 Q2 | - USD | 0.0% |
| 2018 Q1 | - USD | 0.0% |
| 2017 FY | - USD | 0.0% |
| 2017 Q1 | - USD | 0.0% |
| 2017 Q3 | - USD | 0.0% |
| 2017 Q2 | - USD | 0.0% |
| 2017 Q4 | - USD | 0.0% |
| 2016 FY | - USD | 0.0% |
| 2016 Q4 | - USD | 0.0% |
| 2016 Q3 | - USD | 0.0% |
| 2016 Q2 | - USD | 0.0% |
| 2016 Q1 | - USD | 0.0% |
| 2015 FY | - USD | 0.0% |
| 2015 Q4 | - USD | 0.0% |
| 2015 Q3 | - USD | 0.0% |
| 2015 Q2 | - USD | 0.0% |
| 2015 Q1 | - USD | 0.0% |
| 2014 FY | - USD | 0.0% |
| 2014 Q1 | - USD | 0.0% |
| 2014 Q4 | - USD | 0.0% |
| 2014 Q3 | - USD | 0.0% |
| 2014 Q2 | - USD | 0.0% |
| 2013 FY | - USD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Imunon, Inc. | - USD | -Infinity% |
| Homology Medicines, Inc. | -6.65 Million USD | 4168.561% |
| uniQure N.V. | 15.84 Million USD | -1608.01% |
| Abeona Therapeutics Inc. | 3.5 Million USD | -7631.429% |
| Aclaris Therapeutics, Inc. | 31.24 Million USD | -765.948% |
| Agios Pharmaceuticals, Inc. | 26.82 Million USD | -908.836% |
| Amicus Therapeutics, Inc. | 399.35 Million USD | 32.241% |
| Atara Biotherapeutics, Inc. | 8.57 Million USD | -3056.421% |
| bluebird bio, Inc. | 29.49 Million USD | -817.381% |
| Blueprint Medicines Corporation | 249.38 Million USD | -8.509% |
| Cara Therapeutics, Inc. | 20.96 Million USD | -1190.538% |
| Adicet Bio, Inc. | - USD | -Infinity% |
| Dynavax Technologies Corporation | 232.28 Million USD | -16.495% |
| Editas Medicine, Inc. | 78.12 Million USD | -246.377% |
| Esperion Therapeutics, Inc. | 116.33 Million USD | -132.606% |
| Geron Corporation | 237 Thousand USD | -114077.215% |
| Heron Therapeutics, Inc. | 127.04 Million USD | -112.997% |
| Illumina, Inc. | 4.5 Billion USD | 93.992% |
| Iovance Biotherapeutics, Inc. | 1.18 Million USD | -22658.621% |
| IQVIA Holdings Inc. | 14.98 Billion USD | 98.194% |
| Mettler-Toledo International Inc. | 3.78 Billion USD | 92.857% |
| Myriad Genetics, Inc. | 678.4 Million USD | 60.112% |
| Neurocrine Biosciences, Inc. | 1.88 Billion USD | 85.661% |
| Sarepta Therapeutics, Inc. | 1.24 Billion USD | 78.236% |
| Supernus Pharmaceuticals, Inc. | 607.52 Million USD | 55.458% |
| Verastem, Inc. | - USD | -Infinity% |
| Walgreens Boots Alliance, Inc. | 147.65 Billion USD | 99.817% |
| Waters Corporation | 2.95 Billion USD | 90.847% |
| Vertex Pharmaceuticals Incorporated | 9.86 Billion USD | 97.258% |
| Thermo Fisher Scientific Inc. | 42.85 Billion USD | 99.369% |
| Biogen Inc. | 9.83 Billion USD | 97.249% |
| Nektar Therapeutics | 90.12 Million USD | -200.26% |
| Viking Therapeutics, Inc. | - USD | -Infinity% |
| Perrigo Company plc | 4.65 Billion USD | 94.188% |
| Unity Biotechnology, Inc. | - USD | -Infinity% |
| Corbus Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| BioMarin Pharmaceutical Inc. | 2.41 Billion USD | 88.815% |
| Sangamo Therapeutics, Inc. | 176.23 Million USD | -53.548% |
| Evolus, Inc. | 202.08 Million USD | -33.904% |
| Regeneron Pharmaceuticals, Inc. | 13.11 Billion USD | 97.937% |
| FibroGen, Inc. | 147.75 Million USD | -83.145% |
| Agilent Technologies, Inc. | 6.83 Billion USD | 96.04% |
| OPKO Health, Inc. | 863.49 Million USD | 68.662% |
| Alnylam Pharmaceuticals, Inc. | 1.82 Billion USD | 85.199% |
| Exelixis, Inc. | 1.83 Billion USD | 85.215% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| Intellia Therapeutics, Inc. | 36.27 Million USD | -645.968% |
| Zoetis Inc. | 8.54 Billion USD | 96.833% |
| Kala Pharmaceuticals, Inc. | - USD | -Infinity% |
| Ionis Pharmaceuticals, Inc. | 787.64 Million USD | 65.645% |
| Corcept Therapeutics Incorporated | 482.37 Million USD | 43.903% |
| Halozyme Therapeutics, Inc. | 829.25 Million USD | 67.368% |
| Insmed Incorporated | 305.2 Million USD | 11.339% |
| TG Therapeutics, Inc. | 233.66 Million USD | -15.808% |
| Incyte Corporation | 3.69 Billion USD | 92.678% |
| Emergent BioSolutions Inc. | 1.04 Billion USD | 74.211% |